Os 66 melhores médicos de imunoterapia para o cancro da mama do mundo

Professor de Oncologia Médica com mais de 29 anos de experiência no Hospital Gayrettepe Florence Nightingale.

• Especializado em oncologia gastrointestinal
• Formação de fellowship no Instituto de Oncologia da Universidade de Istambul
• Membro da ESMO, ASCO e da Associação Turca de Oncologia Médica

O médico formou-se na Faculdade de Medicina da Universidade de Ancara e completou a residência em medicina interna na Faculdade de Medicina de Ancara GATA. Especializando-se em oncologia médica e hematologia, o médico completou uma bolsa clínica nos EUA. Pioneiro na Turquia, o médico fez parte da equipe que realizou o primeiro transplante de medula óssea no país. O médico atuou como professor visitante em instituições de prestígio em Londres e Suíça. Detentor do Certificado Europeu de Oncologia Médica, o médico é membro fundador tanto da Sociedade Turca de Oncologia Médica quanto do Grupo Oncológico Turco. O foco clínico inclui câncer de mama, gastrointestinal, pulmão, linfomas e mieloma.<\/p>

Especialista em imunoterapia para câncer de mama com foco em diagnóstico molecular e terapias direcionadas no Centro Médico de Solingen.

• Médico-chefe de um centro oncológico interdisciplinar certificado
• Especialista em pesquisa de biologia molecular para tratamento de câncer
• Membro de sociedades oncológicas alemãs e americanas
• Especialista qualificado em genética e cuidados paliativos

Especialista com experiência dedicada em ginecologia oncológica e radioterapia no Sourasky Medical Center.

• Formação especializada em abordagens cirúrgicas e de radioterapia
• Tratamento de casos complexos de cancro da mama que requerem protocolos de tratamento combinados
• Foco em planos de terapia personalizados que integram as mais recentes opções de imunoterapia

A Dra. Séverine Iborra lidera o departamento de ginecologia no Städtisches Klinikum Solingen, com foco em diagnóstico oncológico e tratamento do câncer de mama.

• Certificada em oncologia ginecológica com formação especializada em imunoterapia
• Membro ativo das principais sociedades ginecológicas alemãs
• Utiliza técnicas minimamente invasivas, incluindo o sistema robótico Da Vinci
• Pesquisas publicadas em oncologia molecular e tratamentos ginecológicos

Diretor de internamento oncológico no Centro Médico Tel Aviv – O Dr. Stepfansky lidera a pesquisa e o tratamento de imunoterapia.

• Mais de 15 anos de especialização em oncologia
• Investigador principal em ensaios clínicos de fase 1 a 3
• Formação no renomado departamento de oncologia do Hospital Ichilov
• Certificado (Board-certified) tanto em medicina interna quanto em oncologia

O Dr. Alemdar especializa-se em oncologia médica com foco em imunoterapia para cancro da mama no complexo hospitalar Medical Park Antalya.

• Certificado em oncologia médica desde 2018
• Mais de _doctor_9570_anos_ de experiência em medicina interna e oncologia
• Formado na Universidade de Akdeniz, uma instituição líder na Turquia
• Trabalhou em vários hospitais de prestígio, incluindo o Hospital Universitário de Akdeniz

O Prof. Köstler é especializado em imunoterapia para câncer de mama, combinando mais de 22 anos de experiência clínica com pesquisa de ponta na Wiener Privatklinik.

• Especialista em terapias direcionadas e medicina oncológica personalizada
• Professor associado na Universidade Médica de Viena
• Foca no desenvolvimento de biomarcadores e mecanismos de resistência
• Publica em importantes periódicos internacionais de oncologia

O Dr. Amir é especializado em imunoterapia para o cancro da mama, incluindo terapia direcionada com Keytruda (Pembrolizumab). O seu trabalho inclui mais de 30 apresentações em reuniões científicas.

• Vencedor do prémio ESMO Breast Cancer Translational Research Award
• Bolsa de investigação em cancro da mama na Universidade de Emory
• Membro da Sociedade Europeia de Oncologia Médica (ESMO)
• Investigador publicado com vários prémios de melhor artigo científico

Especialista em cirurgia oncoplástica da mama e técnicas ROLL/SLNB – O Dr. Zengel traz precisão ao tratamento do cancro da mama no Medicalpoint International Hospital.

• _doctor_10177_anos_ de experiência em cirurgia mamária e oncologia
• Especializado em mastectomias com conservação de pele e tecido mamário com reconstrução
• Professor associado de Cirurgia Geral com doutoramento em Oncologia Básica
• Membro de várias associações profissionais, incluindo a Associação de Doenças da Mama de Esmirna

Especialista em câncer de mama, pulmão e gastrointestinal – o Dr. Ozatli traz uma abordagem focada em imunoterapia no Hospital Universitário Istinye Liv.

• Professor associado desde 2016, reconhecido por sua experiência
• Trata casos complexos em um centro oncológico líder
• Experiência em vários departamentos de oncologia turcos
• Formado na Faculdade de Medicina da Universidade de Selcuk

O Professor Cemil Bilir é especializado em oncologia médica, com formação internacional na Cleveland Clinic e na Northeastern University.

• Mais de _doctor_9620_anos_ de experiência em oncologia médica
• Formado nos EUA em instituições de prestígio
• Membro da ASCO e da ESMO
• Atualmente atua como professor na Universidade de Sakarya
• Candidato a doutorado em química inorgânica, o que aprimora as abordagens de tratamento

O Dr. Ercan Ozden é especializado em imunoterapia para câncer de mama no Hospital VM Medical Park Pendik, com ampla formação em oncologia clínica.

• Graduado pela Faculdade de Medicina Cerrahpaşa da Universidade de Istambul
• Concluiu a residência em medicina interna na mesma instituição
• Subespecialização em oncologia clínica na Faculdade de Medicina da Universidade de Kocaeli
• Praticou medicina interna no Hospital Privado Bağcılar Safa e no Hospital Küçükçekmece Batı Bahat

Professor de Oncologia Médica na Universidade de Trakya, especializado em imunoterapia para câncer de mama há mais de 15 anos.

• Fellowship (treinamento de especialização) em oncologia médica na Universidade de Trakya
• Professor Associado e, subsequentemente, Professor de Oncologia Médica de 2010 até o presente
• Extensa experiência no tratamento de câncer de mama com imunoterapia

O Prof. Atci é especializado em oncologia médica, com foco em pesquisa de imunoterapia para câncer de mama no Liv Hospital Topkapı.

• Publicou mais de 19 estudos revisados por pares sobre tratamentos de câncer de mama
• Membro da Sociedade Americana de Oncologia Clínica (ASCO)
• Professor associado de oncologia médica na Universidade İstinye
• Coordenador educacional da subespecialidade de oncologia médica

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

Pesquisador líder em subtipos de câncer de mama – O Dr. Prat concentra-se em traduzir descobertas laboratoriais em abordagens de imunoterapia personalizada no Hospital Quiron Barcelona.

• Chefia o Grupo de Genômica Translacional no IDIBAPS
• Presidente da SOLTI – projeta ensaios clínicos para novos tratamentos de câncer de mama
• Pioneiro na análise de expressão gênica para terapias personalizadas
• Cofundador da Reveal Genomics – detém três patentes em pesquisa de câncer

A Prof. Elke Jaeger é uma das principais oncologistas da Alemanha segundo o ranking da Focus, especializada em imunoterapia de sarcomas e cancro da mama na Clínica Nordwest.

• Chefe de Oncologia e Hematologia na Clínica Nordwest
• 41 anos de experiência em oncologia
• Reconhecida como especialista de topo em sarcomas

O Dr. Osama Abdel Mohimen Mohamed lidera a Unidade de Hematologia no Hospital Oncológico Shefaa Al Orman. Ele trata cânceres sanguíneos complexos, incluindo leucemia, linfoma e mieloma. O Dr. Mohamed é membro da Sociedade Europeia de Oncologia Médica (ESMO). Ele também é membro da Sociedade Americana de Hematologia (ASH) e da ASBMT.

• Especializado em quimioterapia, imunoterapia e transplante de medula óssea.
• Gerencia leucemia aguda agressiva e distúrbios sanguíneos crônicos.
• Trata complicações decorrentes de vários tumores sólidos.
• Trabalha em um centro credenciado pela ESMO que atende 6.000 pacientes anualmente.